Treatment of non alcoholic fatty liver disease with n-3 fatty acids

• Research type

  Research Study

• Full title

  The effects of purified n-3 fatty acids on serum biomarkers and cardiovascular risk markers in a randomized placebo controlled trial in patients with non alcoholic fatty liver disease.

• IRAS ID

  3835

• Contact name

  Byrne C D

• Eudract number

  2008-003766-26

• ISRCTN Number

  N/A

• Clinicaltrials.gov Identifier

  NCT00760513

• Research summary

  Non alcoholic fatty liver disease (NAFLD) imposes a high and increasing burden on the NHS, yet there is presently no licensed treatment or validated approach to management. NAFLD predisposes to increased risk of type 2 diabetes, increased risk of cardiovascular disease and may progress to chronic irreversible liver disease. We aim to test whether treatment with a purified licensed fish oil preparation (n-3 long chain fatty acids) improves NAFLD and a range of risk factors for type 2 diabetes and heart disease.

• REC name

  South Central - Hampshire A Research Ethics Committee

• REC reference

  08/H0502/165

• Date of REC Opinion

  22 Dec 2008

• REC opinion

  Favourable Opinion